AstraZeneca has agreed with Europe’s Inclusive Vaccines Alliance (IVA) that it will supply up to 400 million doses of the University of Oxford’s COVID-19 vaccine to broaden access in the region.
The deal, which will see deliveries start by the end of this year, allows the IVA aims to accelerate the supply of the vaccine and to make it available to other European countries that wish to participate in the initiative.
“This agreement will ensure that hundreds of millions of Europeans have access to Oxford University’s vaccine following approval,” said Pascal Soriot, AZ’ chief executive.
“With our European supply chain due to begin production soon, we hope to make the vaccine available widely and rapidly. I would like to thank the governments of Germany, France, Italy and the Netherlands for their commitment and swift response.”
AstraZeneca is currently working on establishing a number of supply chains in parallel across the world, including for Europe, with total manufacturing capacity currently at two billion doses.
Oxford University has recently begun testing AZD1222 in a Phase II/III UK trial involving around 10,000 adult volunteers, and other late-stage trials are due to begin in a number of countries.
By: Selina McKee
Source: Pharma Times
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.